Cabozantinib: observed
27 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsRecruitingNCT07635316Report a problem
- Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentRecruitingNCT07314164Report a problem
- Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinibRecruitingNCT06548867Report a problem
- International Multicentric Study ARON-1RecruitingNCT05287464Report a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNCT04659343Report a problem
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.CompletedNCT05363072Results postedReport a problem
- Survey of Cabozantinib Used To Treat People With Renal Cell CarcinomaCompletedNCT04804813Results postedReport a problem
- First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainActive, not recruitingNCT07852884Report a problem
- Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination ImmunotherapyCompletedNCT05579847Report a problem
- A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.CompletedNCT05444933Report a problem
- A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in AdultsCompletedNCT05361434Report a problem
- Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular CarcinomaCompletedNCT05100082Report a problem
- Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationCompletedNCT04957160Report a problem
- Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in EnglandCompletedNCT04637204Report a problem
- Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.WithdrawnNCT04609800Report a problem
- Spanish Real-World Evidence CabozantinibCompletedNCT04510688Report a problem
- Cabozantinib in the Elderly With Metastatic Renal Cell CarcinomaCompletedNCT04416646Report a problem
- Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsCompletedNCT04353765Report a problem
- CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional StudyTerminatedNCT04147143Report a problem
- Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)Active, not recruitingNCT04106349Report a problem
- Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.CompletedNCT03744585Report a problem
- A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKCompletedNCT03696407Report a problem
- Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Active, not recruitingNCT03647878Report a problem
- BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)Status unknownNCT03628859Report a problem
- Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaCompletedNCT03419572Report a problem
- Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase InhibitorsStatus unknownNCT01700699Report a problem
- Expanded Access of Cabozantinib in Medullary Thyroid CancerApproved for marketingNCT01683110Report a problem